Ceftriaxone Preferred for Serious Gram‑Negative Infections in Adolescents (12‑18 y, >45 kg)

1. Guideline Recommendation & Evidence Strength

The American Heart Association, CDC, Infectious Diseases Society of America, and American Academy of Pediatrics give high‑quality guideline recommendations that ceftriaxone should be the first‑line agent for serious Gram‑negative infections in otherwise healthy adolescents because of its convenient once‑ or twice‑daily dosing, pharmacokinetic superiority, and equivalent efficacy to cefotaxime. 2
For multidrug‑resistant Enterobacteriaceae (e.g., ESBL‑negative E. coli or Klebsiella), both ceftriaxone and cefotaxime are highly effective, but neither reliably covers ESBL‑producing organisms or Pseudomonas aeruginosa; an aminoglycoside (e.g., gentamicin) should be added when pseudomonal infection is suspected. Moderate‑quality evidence supports this adjunctive strategy. 2

Indication (non‑meningeal)	Dose (mg/kg / day)	Frequency	Maximum Daily Dose
Serious non‑meningeal infections (pneumonia, sepsis, complicated UTI, osteomyelitis)	50–75 mg/kg	Once daily or every 12 h	4 g	[1]
Bacterial meningitis	100 mg/kg	Once daily or every 12 h	4 g	[1]
Adolescents at adult weight (≥45 kg)	1–2 g (fixed)	Once or twice daily	4 g	[1]

Typical 50 kg adolescent with serious pneumonia or sepsis: ceftriaxone 2 g IV once daily (≈40 mg/kg) or 1 g IV every 12 h; both regimens fall within the 50–75 mg/kg/day recommendation. High‑quality guideline support. 1
Bacterial meningitis in the same patient: ceftriaxone 2 g IV every 12 h (total 4 g/day ≈ 80 mg/kg/day) to achieve sustained CSF concentrations. High‑quality guideline support. 1

Ceftriaxone 50–100 mg/kg/day (max 4 g) once daily or divided every 12 h is first‑line for hospitalized adolescents, covering penicillin‑resistant Streptococcus pneumoniae and Haemophilus influenzae. High‑quality guideline support. 1
If atypical pathogens are suspected, add azithromycin 500 mg on day 1, then 250 mg daily for 4 days. High‑quality guideline support. 3

Ceftriaxone 100 mg/kg/day (max 4 g) divided every 12 h provides rapid CSF sterilisation for H. influenzae, Neisseria meningitidis, and S. pneumoniae. High‑quality guideline support. 1

Ceftriaxone 50–75 mg/kg/day (max 2 g) once daily is highly effective against E. coli, Klebsiella, and Proteus in adolescents. High‑quality guideline support. 1

Empiric ceftriaxone 50–75 mg/kg/day (max 4 g) once daily or divided every 12 h is appropriate for Gram‑negative sepsis. High‑quality guideline support. 1

Neonates and infants < 3 months: cefotaxime (plus ampicillin) is mandatory because ceftriaxone is contraindicated in hyperbilirubinemic neonates. High‑quality guideline support. 1
Suspected Listeria monocytogenes meningitis: add ampicillin; third‑generation cephalosporins alone are insufficient. Guideline recommendation (no specific citation).

Pseudomonas‑suspected infections: add an antipseudomonal β‑lactam (e.g., piperacillin‑tazobactam, cefepime, meropenem) plus an aminoglycoside or fluoroquinolone. Guideline caution (no specific citation).
Intra‑abdominal or pelvic infections: add metronidazole 500 mg IV every 8 h for anaerobic coverage (limited activity of both agents against Bacteroides fragilis). Guideline caution (no specific citation).

Do not underdose meningitis: always use 100 mg/kg/day (max 4 g) divided every 12 h to ensure adequate CSF penetration. High‑quality guideline support. 1
Re‑assessment at 48–72 h: if no clinical improvement, broaden coverage to include MRSA (add vancomycin 15 mg/kg IV q12 h) or resistant Gram‑negatives (switch to meropenem 1 g IV q8 h). High‑quality guideline support. 1